Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

Inclusion Criteria:

Males or females, aged >= 18 years at time of consent.
Have a diagnosis of Psoriatic arthritis (PsA) of >= 6 months
Meet the Classification Criteria of PsA (CASPAR) at time of screening
Must not have been adequately treated with a a traditional non-biologic disease modifying anti-rheumatic drug (DMARD).
Concurrent treatment with methotrexate, leflunomide, or sulfasalazine allowed and required
Must not have taken a biologic Tumour Necrosis Factor Inhibitor
Must have 3 or more swollen joints AND 3 or more tender joints
Must have active psoriasis skin lesions

Exclusion Criteria:

Have non-plaque forms of psoriasis, eg erythrodermic, guttate or pustular, with the exception of nail psoriasis which is allowed
Pregnant or breast feeding, females of child-bearing potential not using highly effective contraception
New York Heart Association Class III and IV congestive heart failure
History of hypersensitivity or infusion reaction to biologic agents
Infection with HIV, hepatitis B virus, hepatitis C virus, or other chronic infection